Delayed release
Performances of New Generation of Delayed Release Capsules
... be available in 2015). DRcaps capsules contain a gelling agent in addition to HPMC and have been advertised for nutraceuticals including probiotics enzymes and herbs. While Capsugel indicated that their capsule product ...
9
FORMULATION DEVELOPMENT OF MICROSPONGE BASED DELAYED RELEASE DOSAGE FORM OF LANSOPRAZOLE
... acid release by inhibiting H + , K(+)-adenosine triphosphatase, which is the final step in the secretion of acid 2 ...develop delayed release dosage form, formulation likely to delay drug ...
8
FORMULATION AND EVALUATION OF LANSOPRAZOLE DELAYED RELEASE PELLETS
... drug release to target tissue over a specified period of ...using delayed release products is to protect the drug from gastric fluids, to reduce gastric distress caused by drugs particularly ...
19
Formulation and evaluation of delayed release pellets of rabeprazole sodium
... work was to prepare Delayed release i.e., enteric coated pellets of Rabeprazole sodium by using Methacrylic acid copolymer in Fluid bed processor to prevent degradation in the stomach due to the acidic ...
5
Demonstration of early efficacy results of the delayed release combination of doxylamine pyridoxine for the treatment of nausea and vomiting of pregnancy
... This is a secondary analysis of a double-blind, random- ized, multicenter, placebo-controlled study of the delayed-release combination of doxylamine succinate (10 mg) and pyridoxine hydrochloride (10 mg) ...
5
Metformin hydrochloride delayed release tablets – a comparative dissolution profiles study
... controlled release tablets Glucophage®-Delayed release with a 100 % drug dissolution, has equivalent bioavailability to an aqueous metformin ...
6
DULOXETINE HYDROCHLORIDE DELAYED RELEASE PELLETS PREPARED BY SUSPENSION LAYER METHOD
... using delayed-release product is to protect the drug from gastric fluids, to reduce gastric distress caused by drug particularly irritating to the stomach, and to avoid toxic complex formation or to ...
5
FORMULATION AND EVALUATION OF TIME DELAYED RELEASE TABLET OF CARVEDILOL PHOSPHATE
... Cardiovascular disease like heart failure, hypertension etc. mostly occurs at early morning at around 4.00 am to 5.00 am. So if prepare such a drug delivery system which can be taken by patient at bed time and ...
8
FORMULATION, DEVELOPMENT AND EVALUATION OF DELAYED RELEASE TABLETS OF ASPIRIN USP
... of delayed release tablet of ...that release profile was found to be best with disintegrant ...that release profile of batch ...drug release of ...that release profile of ...
26
Formulation and Evaluation of Delayed Release Tablets of Rabeprazole Sodium
... the delayed release tablets of Rabeprazole sodium, an anti ulcer drug like peptic ulcer and duodenal ...sodium Delayed release tablets were prepared by Direct Compression method using ...
121
FORMULATION AND IN VITRO EVALUATION OF RABEPRAZOLE SODIUM DELAYED RELEASE TABLETS
... vitro release and is comparable to the innovator ...drug release compared to ...Rabeprazole delayed release tablets and comparable to the innovator ...
12
Formulation and Evaluation of Diclofenac Sodium Delayed Release Tablets
... Delayed release tablets of Diclofenac sodium tablets were prepared by wet granulation method using different pH resistant polymers like HPMC, CAP and Eudragit to dissolve it in alkaline ...better ...
6
Formulation and Evaluation of Delayed Release Pantoprazole Sodium Enteric Coated Tablets.
... hydrochloride delayed release enteric coated pellets in ...drug release shows after pH6.5 buffer, where as marketed preparation release starts at pH ...Invitro release studies and were ...
124
<p>Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers</p>
... Oral delayed-release mesalamine, also known as 5-aminosalicylic acid, has been shown to be safe and effective in inducing remission in adults and children and for maintaining remission in adults with ...
9
Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections
... son, posaconazole concentrations were frequently monitored in many patients. While this was justified with the oral suspension due to the significant variability that was observed along with the association between ...
8
Clinical utility of risedronate in postmenopausal osteoporosis: patient considerations with delayed-release formulation
... This paper reviews the different modalities of administration of risedronate and their utility from a clinician’s and patient’s point of view. A literature search in the PubMed database ...
8
FORMULATION AND OPTIMIZATION OF DELAYED RELEASE TABLET CONTAINING DOXYCYCLINE HYCLATE
... and delayed release polymers and their evaluation test are ...of delayed release polymer as a factor and dissolution and drug content as an response were ...drug release and drug ...
24
Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole
... posaconazole delayed-release tablet formulation and reviews the efficacy, safety, and cost-effectiveness of both the oral suspension and the new tablet formu- ...
11
<p>Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis</p>
... patients that are critically ill, and patients that are immu- nocompromised are at increased risk of having inter- individual pharmacokinetic variability. Moreover, these patients have increased clearance and/or ...
7
Management of gastroesophageal reflux disease and erosive esophagitis in pediatric patients: Focus on delayed-release esomeprazole
... The powerful action of PPIs, in addition to elevating gas- tric pH, also leads to reducing 24-hour intragastric volume, facilitating gastric emptying, and reducing refluxate volume. The only PPIs used in children are ...
7